Talzenna (talazoparib) — United Healthcare
breast cancer
Initial criteria
- Diagnosis of breast cancer
- Disease is one of the following: (a) Locally advanced (b) Metastatic
- Presence of a germline BRCA-mutation
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Talzenna therapy
Approval duration
12 months